Polymer-based oral peptide nanomedicines

Therapeutic Delivery

Volumn 3, Issue 5, 2012, Pages 657-668

  Herrero, Edgar P ^a   Alonso, Maria Jose ^a,b   Csaba, Noemi ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTIDIABETIC AGENT; BOVINE SERUM ALBUMIN; CALCITONIN; CAPSULIN; CELL PENETRATING PEPTIDE; CHITOSAN; CYCLOSPORIN A; DESMOPRESSIN; DEXTRAN SULFATE; DIPHTHERIA VACCINE; ELIGEN; ENZYME INHIBITOR; EUDRAGIT; GLUTATHIONE; HDV 1; HEXYL INSULIN MONOCONJUGATE 2; INSULIN; INSULIN VITAMIN B12 CONJUGATE; MELITTIN; NANOCAPSULE; NANOCARRIER; NN 1952; NODIN; OCTREOTIDE; ORADEL; ORMD 0801; PENETRATION ENHANCING AGENT; PEPTIDE; PLATELET DERIVED GROWTH FACTOR BB; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMETHACRYLIC ACID; TETANUS TOXOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

BIOCOMPATIBILITY; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STABILITY; DRUG TRANSPORT; HUMAN; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTESTINE MUCOSA PERMEABILITY; LIPODYSTROPHY; MICROEMULSION; MOLECULAR INTERACTION; NANOEMULSION; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PHYSIOLOGICAL STRESS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW; SIDE EFFECT;

EID: 84861304602     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.40     Document Type: Review

References (137)

1. Walsh G. Biopharmaceutical benchmarks 2006. Nat. Biotechnol. 24(7), 769-776 (2006).
2. Johnson-Leger C, Power CA, Shomade G, Shaw JP, El Proudfoot EI. Protein therapeutics - lessons learned and a view of the future. Exp. Opin. Biol. Ther. 6(1), 1-7 (2006).
3. Degim IT, Celebi N. Controlled delivery of peptides and proteins. Curr. Pharm. Des. 13(1), 99-117 (2007).
4. Reichert J. Development trends for peptide therapeutics: a comprehensive quantitative analysis of peptide therapeutics in clinical development. In: Peptide Therapeutics Foundation. Peptide Therapeutics Foundation, Macmillan Publishers, London, UK (2010).
5. Adessi C, Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9(9), 963-978 (2002).
6. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Ind. J. Pharm. Sci. 70(3), 269-277 (2008).
7. Hoffman A, Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin. Pharm. 33(4), 285-301 (1997).
8. Bernkop-Schnurch A, Walker G. Multifunctional matrices for oral peptide delivery. Crit. Rev. Ther. Drug Carr. Syst. 18(5), 459-501 (2001).
9. Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev. 56(4), 459-480 (2004).
10. Lee VHL, Traver RD, Taub ME. Enzymatic barriers to peptide and protein drug delivery. In: Peptide and Protein Drug Delivery. Lee VHL (Ed.). Marcel Dekker Inc., NY, USA (1991).
11. Woodley JF. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carr. Syst. 11(2-3), 61-95 (1994).
12. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58(1), 15-28 (2006).
13. Ward PD, Tippin TK, Thakker DR. Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm. Sci. Technol. Today 3(10), 346-358 (2000).
14. Borges O, Cordeiro-da-Silva A, Romeijn SG et al. Uptake studies in rat Peyers patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination. J. Control. Release 114(3), 348-358 (2006).
15. Wu ZH, Ping QN, Wei Y, Lai JM. Hypoglycemic efficacy of chitosan-coated insulin liposomes after oral administration in mice. Acta Pharm. Sin. 25(7), 966-972 (2004).
16. Adams G, Wang N, Cui Y. Future alternative therapies in a quest to halt aberrations in diabetes mellitus. Biomed. Pharm. 59(6), 296-301 (2005).
17. Rubio-Aliaga I, Daniel H. Mammalian peptide transporters as targets for drug delivery. Trends Pharm. Sci. 23(9), 434-440 (2002).
18. Maher S, Feighery L, Brayden D, McClean SN. Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae. Pharm. Res. 24(7), 1346-1356 (2007).
19. Maher S, Devocelle M, Ryan SA, McClean SN, Brayden DJ. Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. Int. J. Pharm. 387(1-2), 154-160 (2010).
20. Kamei N, Morishita M, Kanayama Y et al. Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography. J. Control. Release 146(1), 16-22 (2010).
21. Kamei N, Morishita M, Takayama K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J. Control. Release 136(3), 179-186 (2009).
22. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6(9), 688-701 (2006).
23. Kahns AH, Buur A, Bundgaard H. Prodrugs of peptides. Synthesis and evaluation of various esters of desmopressin (dDAVP). Pharm. Res. 10(1), 68-74 (1993).
24. Uchiyama T, Kotani A, Tatsumi H et al. Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characteristics of DADLE derivatives in rats. Pharm. Res. 17(12), 1461-1467 (2000).
25. Asada H, Douen T, Mizokoshi Y et al. Stability of acyl derivatives of insulin in the small intestine: relative importance of insulin association characteristics in aqueous solution. Pharm. Res. 11(8), 1115-1120 (1994).
26. Swaan PW. Recent advances in intestinal macromolecular drug delivery via receptor-mediated transport pathways. Pharm. Res. 15(6), 826-834 (1998).
27. Oh DM, Han HK, Amidon GL. Drug transport and targeting. Intestinal transport. Pharm. Biotechnol. 12, 59-88 (1999).
28. Pauletti GM, Gangwar S, Knipp GT et al. Structural requirements for intestinal absorption of peptide drugs. J. Control. Release 41(1-2), 3-17 (1996).
29. Desai MP, Labhasetwar V, Walter E, Levy RJ, Amidon GL. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14(11), 1568-1573 (1997).
30. Koziara JM, Lockman PR, Allen DD, Mumper RJ. In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20(11), 1772-1778 (2003).
31. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J. Control. Release 78(1-3), 15-24 (2002).
32. Tobío M, Sánchez A, Vila A et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Coll. Surf. B Biointerfaces 18(3-4), 315-323 (2000).
33. Gao H, Wang YN, Fan YG, Ma JB. Synthesis of a biodegradable tadpole-shaped polymer via the coupling reaction of polylactide onto mono(6-(2-aminoethyl)amino-6-deoxy)-cyclodextrin and its properties as the new carrier of protein delivery system. J. Control. Release 107(1), 158-173 (2005).
34. Carino GP, Jacob JS, Mathiowitz E. Nanosphere based oral insulin delivery. J. Control. Release 65(1-2), 261-269 (2000).
35. Cui FD, Tao AJ, Cun DM, Zhang LQ, Shi K. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci. 96(2), 421-427 (2007).
36. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21(1-2), 67-77 (2002).
37. Satheesh Kumar P, Ramakrishna S, Ram Saini T, Diwan PV. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles. Die Pharmazie Int. J. Pharm. Sci. 61(7), 613-617 (2006).
38. Yoo HS, Park TG. Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. J. Pharm. Sci. 93(2), 488-495 (2004
39. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive dl-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Technol. 5(1), 77-85 (2000).
40. Damgé C, Socha M, Ubrich N, Maincent P. Poly(e-caprolactone)/ eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes. J. Pharm. Sci. 99(2), 879-889 (2010).
41. Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117(2), 163-170 (2007).
42. Cui F, Qian F, Zhao Z, Yin L, Tang C, Yin C. Preparation, characterization, and oral delivery of insulin loaded carboxylated chitosan grafted poly(methyl methacrylate) nanoparticles. Biomacromolecules 10(5), 1253-1258 (2009).
43. Sajeesh S, Sharma CP. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int. J. Pharm. 325(1-2), 147-154 (2006).
44. Torres-Lugo M, Peppas NA. Preparation and characterization of P(MAA-g-EG) nanospheres for protein delivery applications. J. Nanopart. Res. 4(1), 73-81 (2002).
45. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv. Drug Deliv. Rev. 55(4), 519-548 (2003).
46. Damgé C, Couvreur P. A new approach for oral administration of insulin using polyalkylcyanoacrylate nanocapsules as a drug carrier. Diabetes 37(2), 246-251 (1988).
47. Lowe PJ, Temple CS. Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats. Blackwell Publishing Ltd, London, UK, 547-552 (1994).
48. Damgé C, Vonderscher J, Marbach P, Pinget M. Poly(alkyl cyanoacrylate) nanocapsules as a delivery system in the rat for octreotide, a long-acting somatostatin analogue. J. Pharm. Pharmacol. 49(10), 949-954 (1997).
49. Graf A, Rades T, Hook SM. Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: optimisation and in vivo evaluation. Eur. J. Pharm. Sci. 37(1), 53-61 (2009).
50. Mesiha MS, Sidhom MB, Fasipe B. Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int. J. Pharm. 288(2), 289-293 (2005).
51. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Preat VR. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116(1), 1-27 (2006).
52. Krause HJ, Schwarz A, Rohdewald P. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int. J. Pharm. 27(2-3), 145-155 (1985).
53. Fonseca C, Simoes SR, Gaspar RR. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release 83(2), 273-286 (2002).
54. Lemoine D, Preat V. Polymeric nanoparticles as delivery system for influenza virus glycoproteins. J. Control. Release 54(1), 15-27 (1998).
55. Leo E, Brina B, Forni F, Vandelli MA. In vitro evaluation of PLA nanoparticles containing a lipophilic drug in water-soluble or insoluble form. Int. J. Pharm. 278(1), 133-141 (2004).
56. Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int. J. Pharm. 275(1-2), 171-187 (2004).
57. Langer RS, Peppas NA. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 2(4), 201-214 (1981).
58. Zambaux MF, Bonneaux F, Gref R, Dellacherie E, Vigneron C. Preparation and characterization of protein C-loaded PLA nanoparticles. J. Control. Release 60(2-3), 179-188 (1999).
59. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. 22(5), 419-464 (2005).
60. Alonso-Sande MA, Cuna M, Remunan-Lopez C, Teijeiro-Osorio DE, Alonso-Lebrero JL, Alonso MAJ. Formation of new glucomannan-chitosan nanoparticles and study of their ability to associate and deliver proteins. Macromolecules 39(12), 4152-4158 (2006).
61. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MAJ. Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines. Pharm. Res. 14(10), 1431-1436 (1997).
62. Calvo P, Remuñán-L0́pez C, Vila-Jato JL, Alonso MJ. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 63(1), 125-132 (1997).
63. Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter JR, Langer K. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials 26(15), 2723-2732 (2005).
64. Reis CP, Ribeiro AJ, Houng S, Veiga F, Neufeld RJ. Nanoparticulate delivery system for insulin: design, characterization and in vitro/in vivo bioactivity. Eur. J. Pharm. Sci. 30(5), 392-397 (2007).
65. Reis CP, Veiga FJ, Ribeiro AJ, Neufeld RJ, Damgé C. Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J. Pharm. Sci. 97(12), 5290-5305 (2008).
66. Chalasani KB, Russell-Jones GJ, Jain AK, Diwan PV, Jain SK. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Control. Release 122(2), 141-150 (2007).
67. Paraj0́ Y, DAngelo I, Welle A, Garcia-Fuentes M, Alonso MJ. Hyaluronic acid/chitosan nanoparticles as delivery vehicles for VEGF and PDGF-BB. Drug Deliv. 17(8), 596-604 (2010).
68. Trapani A, Lopedota A, Franco M et al. A comparative study of chitosan and chitosan/ cyclodextrin nanoparticles as potential carriers for the oral delivery of small peptides. Eur. J. Pharm. Biopharm. 75(1), 26-32 (2010).
69. Bernkop-Schnurch A, Krauland AH, Leitner VM, Palmberger T. Thiomers: potential excipients for non-invasive peptide delivery systems. Eur. J. Pharm. Biopharm. 58(2), 253-263 (2004).
70. Deutel B, Greindl M, Thaurer M, Bernkop-Schnuerch A. Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromolecules 9(1), 278-285 (2008).
71. Roldo M, Hornof M, Caliceti P, Bernkop-Schnurch A. Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation. Eur. J. Pharm. Biopharm. 57(1), 115-121 (2004).
72. Woitiski CB, Neufeld RJ, Ribeiro ANJ, Veiga F. Colloidal carrier integrating biomaterials for oral insulin delivery: influence of component formulation on physicochemical and biological parameters. Acta Biomater. 5(7), 2475-2484 (2009).
73. Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Release 117(3), 421-429 (2007).
74. Reis CP, Ribeiro AJ, Veiga F, Neufeld RJ, Damgé C. Polyelectrolyte biomaterial interactions provide nanoparticulate carrier for oral insulin delivery. Drug Deliv. 15(2), 127-139 (2008).
75. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomed. Nanotechnol. Biol. Med. 2(2), 53-65 (2006).
76. Woitiski CB, Neufeld RJ, Veiga F, Carvalho RA, Figueiredo IV. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharm. Sci. 41(3-4), 556-563 (2010).
77. Florence AT. Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov. Today Technol. 2(1), 75-81 (2005).
78. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 8(10), 3054-3060 (2007).
79. Sarmento B, Ribeiro A, Veiga F, Ferreira D. Development and characterization of new insulin containing polysaccharide nanoparticles. Coll. Surf. B Biointerfaces 53(2), 193-202 (2006).
80. Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res. 24(12), 2198-2206 (2007).
81. Sonaje K, Chen Y-J, Chen H-L et al. Enteric-coated capsules filled with freeze- dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31(12), 3384-3394 (2010).
82. Sonaje K, Lin K-J, Wang J-J et al. Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv. Func. Mater. 20(21), 3695-3700 (2010).
83. Sonaje K, Lin K-J, Wey S-P et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs subcutaneous injection. Biomaterials 31(26), 6849-6858 (2010).
84. Lin Y-H, Mi F-L, Chen C-T et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8(1), 146-152 (2007).
85. Shu S, Zhang X, Teng D, Wang Z, Li C. Polyelectrolyte nanoparticles based on water-soluble chitosan-poly (l-aspartic acid)-polyethylene glycol for controlled protein release. Carbohyd. Res. 344(10), 1197-1204 (2009).
86. Makhlof A, Tozuka Y, Takeuchi H. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery. Eur. J. Pharm. Sci. 42(5), 445-451 (2011).
87. Goycoolea FM, Lollo G, Remunan-Lopez C, Quaglia F, Alonso MJ. Chitosan-alginate blended nanoparticles as carriers for the transmucosal delivery of macromolecules. Biomacromolecules 10(7), 1736-1743 (2009).
88. Krauland AH, Alonso MJ. Chitosan/ cyclodextrin nanoparticles as macromolecular drug delivery system. Int. J. Pharm. 340(1-2), 134-142 (2007).
89. Zhang N, Li J, Jiang W et al. Effective protection and controlled release of insulin by cationic-cyclodextrin polymers from alginate/chitosan nanoparticles. Int. J. Pharm. 393(1-2), 213-219 (2010).
90. Prego C, Fabre M, Torres D, Alonso MJ. Efficacy and mechanism of action of chitosan nanocapsules for oral peptide delivery. Pharm. Res. 23(3), 549-556 (2006).
91. Azevedo J, Sizilio R, Brito M et al. Physical and chemical characterization insulin-loaded chitosan-TPP nanoparticles. J. Therm. Anal. Calorim. 106(3), 685-689 (2011).
92. Avadi MR, Sadeghi AMM, Mohammadpour N et al. Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomed. Nanotechnol. Biol. Med. 6(1), 58-63 (2010).
93. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int. J. Pharm. 296(1-2), 122-132 (2005).
94. Garcia-Fuentes M, Prego C, Torres D, Alonso MJ. A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery. Eur. J. Pharm. Sci. 25(1), 133-143 (2005).
95. Prego C, Garcia M, Torres D, Alonso MJ. Transmucosal macromolecular drug delivery. J. Control. Release 101(1-3), 151-162 (2005).
96. Prego C, Torres D, Alonso MJ. Chitosan nanocapsules as carriers for oral peptide delivery: effect of chitosan molecular weight and type of salt on the in vitro behaviour and in vivo effectiveness. J. Nanosci. Nanotechnol. 6(9-10), 2921-2928 (2006).
97. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int. J. Pharm. 255(1-2), 13-32 (2003).
98. Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso MJ. Development and characterization of CyA-loaded poly(lactic acid):poly(ethylene glycol)PEG micro-and nanoparticles. Comparison with conventional PLA particulate carriers. Eur. J. Pharm. Biopharm. 51(2), 111-118 (2001).
99. Belchetz P, Hammond P. Mosbýs Colour Atlas and Text of Diabetes and Endocrinology. Elsevier Ltd, Burgos, Spain (2004).
100. Wong TW. Design of oral insulin delivery systems. J. Drug Target. 18(2), 79-92 (2010).
101. Gupta A, Jha KK, Arora R. Insulin durg delivery: strategies and technologies. Pharm. Res. 4, 154-168 (2010).
102. Sabetsky V, Ekblom J. Insulin: A new era for an old hormone. Pharm. Res. 161 11-4 2010
103. Thomas F Advances in insulin delivery systems and devices: beyond the vial and syringe. Insulin 1(3), 99-108 (2006).
104. Peppas NA, Kavimandan NJ. Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. Eur. J. Pharm. Sci. 29(3-4), 183-197 (2006).
105. Morishita M, Goto T, Nakamura K, Lowman AM, Takayama K, Peppas NA. Novel oral insulin delivery systems based on complexation polymer hydrogels: single and multiple administration studies in type 1 and 2 diabetic rats. J. Control. Release 110(3), 587-594 (2006).
106. Liu H, Tang R, Pan WS, Zhang Y. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J. Pharm. Pharmacol. 55(11), 1523-1529 (2003).
107. Agarwal V, Reddy IK, Khan MA. Oral delivery of proteins: effect of chicken and duck ovomucoid on the stability of insulin in the presence of a-chymotrypsin and trypsin. Pharm. Pharmacol. Commun. 6(5), 223-227 (2000).
108. Shah RB, Ahsan F, Khan MA. Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug Carrier Syst. 19(2), 135-169 (2002).
109. Li CL, Deng YJ. Oil-based formulations for oral delivery of insulin. J. Pharm. Pharmacol. 56(9), 1101-1107 (2004).
110. Cox DS, Raje S, Gao HL, Salama NN, Eddington ND. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm. Res. 19(11), 1680-1688 (2002).
111. Karyekar CS, Fasano A, Raje S, Lu R, Dowling TC, Eddington ND. Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J. Pharm. Sci. 92(2), 414-423 (2003
112. Eaimtrakarn S, Prasad YVR, Ohno T et al. Absorption enhancing effect of Labrasol on the intestinal absorption of insulin in rats. J. Drug Target. 10(3), 255-260 (2002).
113. Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care 33(6), 1288-1290 (2010).
114. Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J. Control. Release 132(1), 21-25 (2008).
115. Clement S, Dandona P, Still JG, Kosutic G. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 53(1), 54-58 (2004).
116. Hazra P, Adhikary L, Dave N et al. Development of a process to manufacture PEGylated orally bioavailable insulin. Biotechnol. Prog. 26(6), 1695-1704 (2010).
117. Petrus AK, Allis DG, Smith RP, Fairchild TJ, Doyle RP. Exploring the implications of vitamin B12 conjugation to insulin on insulin receptor binding. ChemMedChem 4(3), 421-426 (2009).
118. Wood KM, Stone G, Peppas NA. Lectin functionalized complexation hydrogels for oral protein delivery. J. Control. Release 116(2), 66-68 (2006).
119. Makhlof A, Werle M, Tozuka Y, Takeuchi H. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Control. Release 149(1), 81-88 (2011).
120. Geho WB, Geho HC, Lau JR, Gana TJ. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. Diabetes Technol. Soc. 3(6), 1451-1459 (2009).
121. Woitiski CB, Carvalho RA, Ribeiro AJ, Neufeld RJ, Veiga F. Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 22(4), 223-237 (2008).
122. Li M-G, Lu W-L, Wang H-C et al. Distribution, transition, adhesion and release of insulin loaded nanoparticles in the gut of rats. Int. J. Pharm. 329(1-2), 182-191 (2007).
123. Davaran S, Omidi Y, Rashidi MR et al. Preparation and in vitro evaluation of linear and star-branched PLGA nanoparticles for insulin delivery. J. Bioact. Compat. Polym. 23(2), 115-131 (2008).
124. Xiong XY, Li YP, Li ZL et al. Vesicles from pluronic/poly(lactic acid) block copolymers as new carriers for oral insulin delivery. J. Control. Release 120(1-2), 11-17 (2007).
125. Pan Y, Li YJ, Zhao HY et al. Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int. J. Pharm. 249(1-2), 139-147 (2002).
126. Prego C, Torres D, Alonso MJ. The potential of chitosan for the oral administration of peptides. Exp. Opin. Drug Deliv. 2(5), 843-854 (2005).
127. Csaba N, Garcia-Fuentes M, Alonso MJ. The performance of nanocarriers for transmucosal drug delivery. Exp. Opin. Drug Deliv. 3(4), 463-478 (2006).
128. de la Fuente M, Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles as protein and gene carriers to mucosal surfaces. Nanomedicine 3(6), 845-857 (2008).
129. Krauland AH, Guggi D, Bernkop-Schnurch A. Oral insulin delivery: the potential of thiolated chitosan-insulin tablets on non-diabetic rats. J. Control. Release 95(3), 547-555 (2004).
130. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv. Drug Deliv. Rev. 57(11), 1569-1582 (2005).
131. Werle M, Takeuchi H, Bernkop-Schnürch A. Modified chitosans for oral drug delivery. J. Pharm. Sci. 98(5), 1643-1656 (2009).
132. Rekha MR, Sharma CP. Synthesis and evaluation of lauryl succinyl chitosan particles towards oral insulin delivery and absorption. J. Control. Release 135(2), 144-151 (2009).
133. Sonaje K, Lin Y-H, Juang J-H, Wey S-P, Chen C-T, Sung H-W. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30(12), 2329-2339 (2009).
134. Woitiski CB, Sarmento B, Carvalho RA, Neufeld RJ, Veiga F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int. J. Pharm. 412(1-2), 123-131 (2011).
135. Varela MC, Guzman M, Molpeceres J, del Rosario Aberturas M, Rodriguez-Puyol D, Rodriguez-Puyol M. Cyclosporine-loaded polycaprolactone nanoparticles: immunosuppression and nephrotoxicity in rats. Eur. J. Pharm. Sci. 12(4), 471-478 (2001).
136. Graf A, McDowell A, Rades T. Poly(alkycyanoacrylate) nanoparticles for enhanced delivery of therapeutics: is there real potential? Exp. Opin. Drug Deliv. 6(4), 371-387 (2009).
137. El-Shabouri MH. Positively charged nanoparticles for improving the oral bioavailability of cyclosporin-A. Int. J. Pharm. 249(1-2), 101-108 (2002)